- HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
-
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
-
J Pathol Transl Med. 2020;54(1):34-44. Published online November 6, 2019
-
DOI: https://doi.org/10.4132/jptm.2019.11.03
-
-
18,510
View
-
1,050
Download
-
104
Web of Science
-
103
Crossref
-
Abstract
PDF
- Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.
-
Citations
Citations to this article as recorded by
- Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco Virchows Archiv.2024; 484(1): 3. CrossRef - Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup The Journal of Molecular Diagnostics.2024; 26(1): 61. CrossRef - Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White Annals of Surgical Oncology.2024; 31(1): 376. CrossRef - Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo Breast Cancer Research and Treatment.2024; 204(1): 89. CrossRef - Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol npj Breast Cancer.2024;[Epub] CrossRef - Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang The Journal of Applied Laboratory Medicine.2024; 9(1): 76. CrossRef - High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels Biomedical Optics Express.2024; 15(2): 900. CrossRef - HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen Pathology.2024; 56(3): 334. CrossRef - Fast-tracking drug development with biomarkers and companion diagnostics
Noreen McBrearty, Devika Bahal, Suso Platero Journal of Cancer Metastasis and Treatment.2024;[Epub] CrossRef - Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann Archives of Pathology & Laboratory Medicine.2024; 148(2): 242. CrossRef - Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung Cancers.2024; 16(3): 518. CrossRef - Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe Clinical Nuclear Medicine.2024; 49(4): e149. CrossRef - Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina International Journal of Molecular Sciences.2024; 25(5): 2649. CrossRef - The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos Journal of Cutaneous Pathology.2024;[Epub] CrossRef - Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
Jing Wang, Esther Yoon, Savitri Krishnamurthy Annals of Diagnostic Pathology.2024; 70: 152288. CrossRef - Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao Breast Cancer Research.2024;[Epub] CrossRef - Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao Cancer Biotherapy and Radiopharmaceuticals.2024;[Epub] CrossRef - Clinicopathological and prognostic significance of VEGF, PDGF-B, and HER2/neu expression in gallbladder cancer
Pooja Shukla, Kumudesh Mishra, Ratnakar Shukla, Ruchira Vishwakarma, Niraj Kumari, Narendra Krishnani, Anu Behari, Vinay K. Kapoor Journal of Cancer Research and Therapeutics.2024; 20(1): 349. CrossRef - Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
G. Curigliano, R. Dent, H. Earle, S. Modi, P. Tarantino, G. Viale, S.M. Tolaney ESMO Open.2024; 9(4): 102989. CrossRef - Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: an analysis focusing on the HER2-low status
Sei Na, Milim Kim, Yujun Park, Hyun Jung Kwon, Hee-Chul Shin, Eun-Kyu Kim, Mijung Jang, Sun Mi Kim, So Yeon Park Breast Cancer.2024;[Epub] CrossRef - Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
Suji Lee, Jee Yeon Kim, So Jeong Lee, Chung Su Hwang, Hyun Jung Lee, Kyung Bin Kim, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Chang Hun Lee, Gi Yeong Huh, Ahrong Kim Medicina.2024; 60(5): 737. CrossRef - Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga Annals of Surgical Oncology.2023; 30(13): 8371. CrossRef - Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang European Radiology.2023; 34(2): 899. CrossRef - Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
Lan Deng, Le Zhao, Lifen Liu, Haomin Huang Open Life Sciences.2023;[Epub] CrossRef - HER2-low expression in patients with advanced or metastatic solid tumors
B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer Annals of Oncology.2023; 34(11): 1035. CrossRef - Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt Data in Brief.2023; 46: 108880. CrossRef - Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely Diagnostics.2023; 13(1): 168. CrossRef - Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez G3.2023;[Epub] CrossRef - Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet ACS Sensors.2023; 8(3): 1200. CrossRef - Single-cell HER2 quantification via instant signal amplification in microdroplets
Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang Analytica Chimica Acta.2023; 1251: 340976. CrossRef - Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
Daniela Miladinova Frontiers in Molecular Biosciences.2023;[Epub] CrossRef - CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
Yassir Alaa Muhammed Hassan Shubbar Wiadomości Lekarskie.2023; 76(1): 97. CrossRef - Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco Frontiers in Molecular Biosciences.2023;[Epub] CrossRef - Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira Animals.2023; 13(8): 1384. CrossRef - Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen Breast Cancer: Targets and Therapy.2023; Volume 15: 281. CrossRef - HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić International Journal of Molecular Sciences.2023; 24(9): 8206. CrossRef - HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
Aditya Bardia, Giuseppe Viale Targeted Oncology.2023; 18(3): 313. CrossRef - Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday Acta Veterinaria Brno.2023; 92(2): 143. CrossRef - Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
Timothy Qi, Yanguang Cao European Journal of Pharmaceutical Sciences.2023; 186: 106467. CrossRef - The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar Clinical Breast Cancer.2023; 23(6): 567. CrossRef - Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
Hao Wang, Hailing Cao, Zhiyun Guo Oncology Letters.2023;[Epub] CrossRef - Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
Faris Alrumaihi Journal of Biomolecular Structure and Dynamics.2023; : 1. CrossRef - Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang Molecular Cancer.2023;[Epub] CrossRef - Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao Computerized Medical Imaging and Graphics.2023; 108: 102270. CrossRef - Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova Journal of Personalized Medicine.2023; 13(7): 1176. CrossRef - HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555. CrossRef - Discordance of HER2 Expression and/or Amplification on Repeat Testing
Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam Molecular Cancer Therapeutics.2023; 22(8): 976. CrossRef - Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari International Journal of Molecular Sciences.2023; 24(16): 12795. CrossRef - Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang BMC Cancer.2023;[Epub] CrossRef - Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani International Immunopharmacology.2023; 124: 110999. CrossRef - Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi Bulletin du Cancer.2023; 110(12): 1301. CrossRef - HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger Virchows Archiv.2023;[Epub] CrossRef - Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux Biomedicines.2023; 11(12): 3164. CrossRef - Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib ACS Biomaterials Science & Engineering.2022; 8(2): 871. CrossRef - A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi Nanotechnology Reviews.2022; 11(1): 793. CrossRef - Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie S. Wynn, Shou-Ching Tang Cancer and Metastasis Reviews.2022; 41(1): 193. CrossRef - Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks Sensors & Diagnostics.2022; 1(3): 405. CrossRef - FTO genotype was associated with breast cancer in HER2 negative patients
Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei Clinical Nutrition ESPEN.2022; 49: 495. CrossRef - Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352. CrossRef - Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens Cancer Treatment Reviews.2022; 106: 102384. CrossRef - RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu Frontiers in Surgery.2022;[Epub] CrossRef - Use of Radionuclide-Based Imaging Methods in Breast Cancer
Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy Seminars in Nuclear Medicine.2022; 52(5): 561. CrossRef - Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao Scientific Reports.2022;[Epub] CrossRef - Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
Anastasia Alataki, Mitch Dowsett Endocrine-Related Cancer.2022; 29(8): R105. CrossRef - The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev Acta Naturae.2022; 14(2): 4. CrossRef - Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong Modern Pathology.2022; 35(10): 1458. CrossRef - Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman The Breast.2022; 66: 145. CrossRef - Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej Contrast Media & Molecular Imaging.2022; 2022: 1. CrossRef - High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi Lab on a Chip.2022; 22(21): 4129. CrossRef - Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel South Asian Journal of Cancer.2022; 11(04): 281. CrossRef - S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André Oncology Letters.2022;[Epub] CrossRef - Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo PLOS Computational Biology.2022; 18(8): e1010438. CrossRef - Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev Bulletin of Siberian Medicine.2022; 21(3): 132. CrossRef - Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo Journal of Gastric Cancer.2022; 22(4): 264. CrossRef - Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon Nature Genetics.2022; 54(12): 1839. CrossRef - Advanced diagnosis technologies for HER2 breast cancer markers
Mengxue Zhang Highlights in Science, Engineering and Technology.2022; 14: 44. CrossRef - An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale JAMA Oncology.2022; 8(11): 1676. CrossRef - Development of T-cell engagers selective for cells co-expressing two antigens
Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard mAbs.2022;[Epub] CrossRef - The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita Medical Oncology.2022;[Epub] CrossRef - Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia The Cancer Journal.2022; 28(6): 423. CrossRef - The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder Diagnostics.2022; 12(12): 3042. CrossRef - Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li Systematic Reviews.2022;[Epub] CrossRef - Interactions dietary components with expression level of breast cancer-related genes
Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef - HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371. CrossRef - Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart Cancer Treatment Reviews.2021; 99: 102229. CrossRef - Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster The American Journal of Dermatopathology.2021; 43(6): 401. CrossRef - Standardized pathology report for breast cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon Journal of Pathology and Translational Medicine.2021; 55(1): 1. CrossRef - The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
R. Bonfiglio, M.L. Di Pietro Seminars in Cancer Biology.2021; 72: 11. CrossRef - The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian Cancer Management and Research.2021; Volume 13: 6123. CrossRef - Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González Talanta.2021; 235: 122773. CrossRef - Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao Molecular Pharmaceutics.2021; 18(9): 3616. CrossRef - WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan Bulletin du Cancer.2021;[Epub] CrossRef - Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd British Journal of Cancer.2021; 124(11): 1836. CrossRef - Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau Journal of Surgical Oncology.2021; 124(8): 1224. CrossRef - Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu Frontiers in Oncology.2021;[Epub] CrossRef - tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song Thoracic Cancer.2021; 12(17): 2314. CrossRef - Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers ESMO Open.2021; 6(4): 100203. CrossRef - Standardized Pathology Report for Breast Cancer
Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon Journal of Breast Cancer.2021; 24(1): 1. CrossRef - Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan Journal of Translational Medicine.2021;[Epub] CrossRef - Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan Bulletin du Cancer.2021; 108(11): 11S8. CrossRef - HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
SureshKumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, VijayM Patil, Amit Joshi, Kumar Prabhash Cancer Research, Statistics, and Treatment.2021; 4(2): 374. CrossRef - UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V. Molecules.2020; 25(18): 4302. CrossRef - Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae Journal of Breast Cancer.2020; 23(5): 484. CrossRef
|